Levetiracetam Solution
Product Images NDC 55154-4316

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55154-4316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (Image 01)

Drug facts panel for Levetiracetam oral solution USP, labeled as 500 mg per 5 mL in 5 unit dose cups. The panel includes dosage storage instructions (store at 20° to 25°C), a warning that the unit dose packaging is not child resistant and intended for institutional use, and distribution details by Major Pharmaceuticals and Cardinal Health.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure diagram of levetiracetam, showing its molecular arrangement with labeled chemical groups including a lactam ring and side chains represented by CH3, CH2, H, and CONH2.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A bar graph comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows percentages ranging from 0% to 45%, with Levetiracetam 1000 mg/day and 3000 mg/day groups having notably higher percentages than the placebo group.*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar graph comparing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The y-axis represents percentage of patients from 0% to 45%, and the x-axis indicates the treatment groups with their sample sizes.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar chart comparing the percentage of patients between a placebo group and a Levetiracetam 3000 mg/day group. The placebo group's bar shows 14.4%, while the Levetiracetam group's bar shows 39.4%, indicating a notable difference between the two groups.*

FDA Label Image

Figure 4 (Levetiracetam 05)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The chart shows approximately 19.6% for the placebo group and 44.6% for the Levetiracetam group, with an asterisk indicating statistical significance for the Levetiracetam group.*

FDA Label Image

Figure 5 (Levetiracetam 06)

A bar chart comparing the percentage of patients between two groups: Placebo (51 patients) and Levetiracetam (58 patients). The Levetiracetam group shows a higher percentage (43.1%) compared to the Placebo group (19.6%), with a statistical significance indicated by an asterisk.*

FDA Label Image

Figure 6 (Levetiracetam 07)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) at 45.2% and Levetiracetam (N=79) at 72.2%. The y-axis represents the percentage of patients from 0% to 100%. A symbol indicates statistical significance on the Levetiracetam bar.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.